When a blockbuster drug loses patent protection, brand companies face a tough choice: watch revenue drop by 80-90% or find a way to stay competitive. Many choose to launch their own generic version-called authorized generics-to protect profits while keeping prices low for consumers. But why would a brand company sell its own generic? Let’s break down the strategy.

What Exactly Are Authorized Generics?

Authorized generics are exact copies of brand-name drugs sold under generic pricing. Unlike traditional generics, they’re made by the original brand company and use the same formula-active and inactive ingredients-without needing separate FDA approval. They’re marketed under the brand’s New Drug Application (NDA), so they’re identical to the branded version except for the label.

For example, Greenstone Pharmaceuticals (a Pfizer subsidiary) sells the authorized generic for Celebrex (celecoxib). It looks like the original Celebrex pill but has different markings and is sold at generic prices. This means patients get the exact same medication they trusted, but without the brand-name markup.

How Authorized Generics Protect Revenue

When patents expire, brand companies lose most of their revenue fast. For a drug with $1 billion in annual sales, a 90% drop means losing $900 million. Authorized generics let these companies capture part of the generic market they’d otherwise lose entirely. Health Affairs (2022) found that between 2010 and 2019, 854 authorized generics launched in the U.S., with peak activity in 2014. This strategy keeps some revenue flowing while preventing competitors from monopolizing the market.

Here’s how it works: Instead of letting a single generic manufacturer take 100% of the market during the 180-day exclusivity period under the Hatch-Waxman Act, the brand company launches its own authorized generic. This forces the first generic maker to lower prices immediately. Federal Trade Commission data from 2011 showed prices dropped 15-20% faster in markets with authorized generics compared to those without them.

The Hatch-Waxman Act and Market Competition

The Hatch-Waxman Act of 1984 created rules for generic drug approval. It gives the first generic manufacturer 180 days of exclusivity to sell their version before others enter. But brand companies exploit this by launching authorized generics before or during this period. Health Affairs (2022) reports that 70% of authorized generics in markets with this exclusivity launched before or during the 180-day window.

For instance, when Concerta (methylphenidate ER) faced generic competition, Watson/Actavis (now part of Teva) launched its own authorized generic. This kept prices lower than if only one generic company had controlled the market. Patients paid less, and the brand company retained some market share instead of losing everything.

Market Segmentation Strategy

Brand companies use authorized generics to split the market. They keep the premium-priced brand for patients and insurers willing to pay more, while offering the authorized generic to cost-sensitive buyers. This is called price discrimination. For example, a patient might choose the brand-name drug for perceived reliability, while a Medicaid patient gets the authorized generic at a lower cost.

Roper Public Affairs & Media’s 2005 study found over 80% of Americans want the option of authorized generics. This isn’t surprising-patients know these versions match the brand’s exact formula. For drugs with narrow therapeutic indices (like blood thinners), where tiny formulation differences can cause problems, authorized generics ensure continuity of care without switching risks.

Real-World Examples in Action

• Celebrex (celecoxib): Greenstone Pharmaceuticals sells the authorized generic, which is identical to the brand but at generic prices. This helped Pfizer maintain market share after patent expiration.
• Colcrys (colchicine): Prasco Laboratories’ authorized generic version cut the drug’s price from $300 to $10 per pill, making it accessible for gout patients.
• Concerta (methylphenidate ER): Watson/Actavis’ authorized generic prevented a single generic company from monopolizing the market, keeping prices competitive.

These examples show how authorized generics balance patient access, brand revenue, and market competition. They’re not just about saving money-they’re a calculated business move that keeps the system working for everyone.

Regulatory Advantages Over Traditional Generics

Traditional generics must prove bioequivalence through the lengthy ANDA process, which takes 18-24 months. Authorized generics skip this because they operate under the original brand’s NDA. This lets brand companies respond faster to competition. US Pharmacist (2020) notes this is crucial for drugs where minor formulation differences could affect outcomes.

For example, a traditional generic for a heart medication might use different inactive ingredients, potentially altering how the drug works. Authorized generics avoid this risk entirely. The FDA requires brand companies to notify them before launching an authorized generic, but no separate approval is needed. This speed and precision make authorized generics a powerful tool against generic competitors.

Future Trends in Authorized Generics

Recent data shows brand companies are launching authorized generics earlier-sometimes before generic competition even starts. AmerisourceBergen’s 2023 analysis found this preemptive strategy is becoming more common. For instance, some companies now release authorized generics months before the patent expires to lock in market share.

As specialty drugs and biologics face patent cliffs, the strategy is evolving. Evaluate Pharma (2023) predicts "authorized biosimilars" for biologic drugs, though regulatory pathways are still unclear. The FTC continues monitoring this space, but evidence shows net consumer benefits through lower prices. With more complex reimbursement models, authorized generics will likely adapt to value-based pricing, ensuring patients get affordable, high-quality care.

Comparison: Authorized vs. Traditional Generics